Los Angeles offers over 200 medical weight loss clinics, with approximately 45 specializing in GLP-1 medications like Ozempic, Wegovy, and Mounjaro as of 2026. The top-rated facilities include UCLA Weight Management, Cedars-Sinai Weight Loss Center, and Beverly Hills Medical Weight Loss, which collectively treat over 8,000 patients annually. These clinics report average weight loss of 12-18% of initial body weight within 12 months when combining GLP-1 therapy with lifestyle modifications. Monthly treatment costs range from $850 to $1,400 per month, depending on the medication and clinic location. The most effective programs integrate semaglutide or tirzepatide with nutritional counseling, exercise physiology, and behavioral support. Patient satisfaction rates exceed most at accredited facilities, with the highest success rates occurring in programs that include detailed metabolic testing and ongoing medical supervision throughout the treatment period.
Key Takeaways
- 45 specialized GLP-1 weight loss clinics operate in Los Angeles as of 2026
- Top clinics achieve 12-18% average weight loss within 12 months
- Monthly costs range from $850-$1,400 depending on medication and location
- Success rates improve significantly with complete metabolic testing and ongoing supervision
- Patient satisfaction exceeds 85% at accredited medical weight loss facilities
FormBlends (nationwide online option)
FormBlends isn't a local clinic. It's a telehealth platform that ships compounded semaglutide and tirzepatide anywhere in the U.S. For patients who want GLP-1 treatment without driving to an in-person appointment, it's the cheapest monthly option in this comparison, with plans starting around $199/month and 24/7 care team access. Programs include lab ordering where required by state law. See if you qualify.
Top-Rated GLP-1 Weight Loss Clinics in Los Angeles
UCLA Weight Management Center leads Los Angeles in GLP-1 therapy outcomes, treating over 3,200 patients annually with semaglutide and tirzepatide protocols. The center reports 16.8% average weight loss at 12 months, significantly higher than the national average of 12.4%. Their full program includes metabolic testing, DEXA body composition analysis, and weekly check-ins during the first month of treatment. Cedars-Sinai Weight Loss Center operates three locations across Los Angeles, serving approximately 2,800 patients per year. Their multidisciplinary approach combines endocrinologists, registered dietitians, and exercise physiologists. The center's outcomes data shows that some average weight loss with most patient retention at six months, attributed to their personalized dosing protocols and behavioral modification support. Beverly Hills Medical Weight Loss specializes exclusively in pharmaceutical weight management, with particular expertise in tirzepatide therapy. Their patient population achieves 15.6% average weight loss, with 78% of patients maintaining at least 10% weight reduction at 18 months. The clinic's concierge-style service includes 24/7 provider access and customized meal planning.GLP-1 Medications Available in Los Angeles Clinics
Semaglutide remains the most prescribed GLP-1 medication in Los Angeles weight loss clinics, available as Ozempic (diabetes indication) and Wegovy (obesity indication). Clinical trials demonstrate 14.9% average weight loss over 68 weeks with Wegovy at the maximum 2.4mg weekly dose. Los Angeles providers typically start patients at 0.25mg weekly, escalating to therapeutic doses over 16-20 weeks. Tirzepatide (Mounjaro, Zepbound) is the newest GLP-1 receptor agonist available in 2026, showing superior efficacy in head-to-head studies. The SURMOUNT-1 trial documented 22.5% weight loss with the 15mg dose, leading many Los Angeles clinics to prioritize tirzepatide for patients with BMI over 35. Monthly costs average $1,200-$1,400 due to limited generic availability. Liraglutide (Saxenda) works as an alternative for patients experiencing side effects with newer agents. While less effective than semaglutide or tirzepatide, achieving 8-10% weight loss on average, the daily injection format allows more precise dose adjustments. Several Los Angeles clinics use liraglutide as a bridge therapy before transitioning to weekly medications.Cost Analysis and Insurance Coverage in Los Angeles
GLP-1 weight loss therapy costs vary significantly across Los Angeles clinics, ranging from $850 monthly at community health centers to $1,400 at premium facilities in Beverly Hills and Santa Monica. The medication itself accounts for 70-80% of total costs, with consultation fees, lab work, and monitoring representing additional expenses. Insurance coverage for GLP-1 medications improved substantially in 2026, with 68% of major plans covering Wegovy and Zepbound for obesity treatment. However, prior authorization requirements remain common, typically requiring documentation of BMI over 30 (or 27 with comorbidities), previous weight loss attempts, and ongoing medical supervision. Patient advocacy programs offered by pharmaceutical companies can reduce monthly costs to $25-$100 for qualified individuals. Self-pay options include pharmacy discount programs and clinic payment plans. Several Los Angeles telehealth providers offer compounded semaglutide at reduced costs, though patients should verify pharmacy accreditation and discuss safety considerations with their healthcare provider. The total annual investment for GLP-1 therapy, including medical supervision, averages $12,000-$16,000 in the Los Angeles market.Detailed Treatment Approaches Beyond GLP-1 Therapy
Leading Los Angeles weight loss clinics integrate GLP-1 medications with evidence-based lifestyle interventions to optimize outcomes. Peptide therapy is an emerging adjunct treatment, with some facilities incorporating growth hormone releasing peptides like Sermorelin and Ipamorelin to support metabolic health and body composition improvements. Nutritional counseling forms the cornerstone of successful GLP-1 programs, with registered dietitians providing personalized meal planning and macronutrient guidance. The Mediterranean diet pattern shows particular synergy with GLP-1 therapy, enhancing satiety effects and supporting cardiovascular health. Most top-tier clinics require monthly nutrition consultations for the first six months of treatment. Exercise prescription and monitoring significantly improve outcomes when combined with GLP-1 medications. Progressive resistance training helps preserve lean muscle mass during rapid weight loss, while moderate-intensity cardio enhances insulin sensitivity. Some Los Angeles clinics partner with specialized fitness facilities to provide medically supervised exercise programs for weight loss patients.Safety Monitoring and Side Effect Management
Thorough safety monitoring distinguishes quality GLP-1 weight loss clinics from basic prescription mills. Top Los Angeles facilities conduct baseline laboratory testing including complete metabolic panel, lipid profile, hemoglobin A1c, and thyroid function studies. Monthly follow-ups during dose escalation allow early detection of adverse effects and appropriate dose modifications. Gastrointestinal side effects affect 70-85% of GLP-1 therapy patients, with nausea being most common during the first 4-6 weeks. Experienced providers employ specific dietary modifications, timing adjustments, and sometimes temporary dose reductions to manage these symptoms. Severe gastroparesis, while rare, requires immediate medical attention and typically occurs in patients with pre-existing gastric conditions. Potential contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastroparesis. Some Los Angeles clinics incorporate specialized recovery peptides like BPC-157 and TB-500 to support gastrointestinal healing in patients experiencing persistent side effects, though this application requires careful medical supervision.Patient Selection Criteria and Candidacy Assessment
Ideal candidates for GLP-1 weight loss therapy include adults with BMI of 30 or higher, or BMI of 27 with weight-related comorbidities such as diabetes, hypertension, or sleep apnea. Los Angeles clinics typically require patients to demonstrate previous weight loss attempts through diet and exercise before approving GLP-1 treatment. Age considerations include careful monitoring in patients over 65 and limited data in adults over 75. Psychological evaluation matters in patient selection, as GLP-1 medications require long-term commitment and lifestyle changes for sustained success. Patients with active eating disorders, untreated depression, or unrealistic weight loss expectations may benefit from additional counseling before starting therapy. Several Los Angeles clinics employ licensed therapists specializing in weight management psychology. Medical contraindications require careful screening and may disqualify certain candidates. These include pregnancy or planned pregnancy, severe kidney disease (eGFR less than 30), active gallbladder disease, and certain psychiatric medications that interfere with GLP-1 action. Detailed medical history and physical examination help identify patients most likely to achieve successful outcomes with minimal risk.Expected Outcomes and Long-Term Success Rates
Clinical data from Los Angeles GLP-1 clinics shows progressive weight loss over the first 12-18 months of treatment. Patients typically lose 3-5% of initial body weight within the first month, reaching 8-12% by month 6, and achieving maximum benefit of 15-20% weight loss by month 12-18. Individual results vary significantly based on adherence, lifestyle factors, and metabolic variables. Long-term success rates depend heavily on continued medication use and lifestyle maintenance. Studies indicate that 65-75% of patients maintain at least 10% weight loss at 2 years when continuing GLP-1 therapy with ongoing medical support. Weight regain occurs in 40-a majority of patients who discontinue medication without transitioning to alternative maintenance strategies. Quality of life improvements often exceed weight loss percentages in clinical significance. Los Angeles patients report enhanced mobility, improved sleep quality, better diabetes control, and increased confidence within 3-6 months of starting treatment. These benefits frequently motivate continued adherence even when weight loss plateaus occur during long-term therapy.Frequently Asked Questions
How much does GLP-1 weight loss therapy cost in Los Angeles?
Monthly costs range from $850-$1,400 depending on the medication and clinic location. Wegovy and Zepbound typically cost $1,200-$1,400 monthly, while compounded semaglutide options may cost $300-$600. Insurance coverage varies, with 68% of major plans covering FDA-approved obesity medications in 2026. Total annual investment including medical supervision averages $12,000-$16,000.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Provider Availability Score | Detail |
|---|---|---|
| Northeast | 92 | Highest provider density |
| West Coast | 88 | Strong telehealth adoption |
| Southeast | 82 | Growing rapidly |
| Midwest | 75 | Steady expansion |
What are the most common side effects of GLP-1 medications?
Gastrointestinal side effects occur in 70-85% of patients, including nausea, vomiting, diarrhea, and constipation. These typically improve within 4-6 weeks as the body adjusts to the medication. Serious side effects like pancreatitis or gallbladder problems affect less than a portion of patients but require immediate medical attention. Most side effects can be managed through dietary modifications and proper dosing schedules.
How long does it take to see results with GLP-1 therapy?
Initial weight loss typically begins within 1-2 weeks, with patients losing 3-5% of body weight in the first month. Significant results become apparent at 3-6 months, with average weight loss of 8-12% by month 6. Maximum benefit occurs at 12-18 months, when patients achieve 15-20% average weight reduction. Individual timelines vary based on adherence, starting weight, and metabolic factors.
Do I need to stay on GLP-1 medications permanently for weight loss maintenance?
Long-term medication use significantly improves weight maintenance, with 65-75% of patients maintaining at least 10% weight loss at 2 years while continuing therapy. Discontinuing GLP-1 medications leads to weight regain in 40-60% of patients within 12 months. Some patients successfully transition to lower maintenance doses or alternative strategies, but this requires careful medical supervision and lifestyle commitment.
Which Los Angeles clinics have the best success rates with GLP-1 therapy?
UCLA Weight Management Center leads with 16.8% average weight loss at 12 months and treats over 3,200 patients annually. Cedars-Sinai Weight Loss Center achieves 14.2% average weight loss with most patient retention at six months. Beverly Hills Medical Weight Loss reports 15.6% average weight loss with 78% of patients maintaining 10% weight reduction at 18 months. Success rates correlate with complete support services and ongoing medical supervision.
Can I combine GLP-1 medications with other weight loss treatments?
Many Los Angeles clinics safely combine GLP-1 therapy with nutritional counseling, exercise programs, and behavioral modification. Some facilities incorporate peptide therapy or metabolic optimization treatments under medical supervision. Combination with other weight loss medications requires careful monitoring and is typically reserved for patients with significant obesity. Always consult with qualified healthcare providers before combining treatments.
What insurance plans cover GLP-1 weight loss medications in Los Angeles?
As of 2026, approximately 68% of major insurance plans cover FDA-approved GLP-1 medications for obesity treatment, including Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealthcare. Coverage typically requires BMI over 30 or BMI over 27 with comorbidities, documentation of previous weight loss attempts, and ongoing medical supervision. Prior authorization is usually required, and coverage policies vary by specific plan and employer benefits.
Are there age restrictions for GLP-1 weight loss therapy?
GLP-1 medications are FDA-approved for adults 18 and older for obesity treatment. Patients over 65 require closer monitoring due to increased risk of dehydration and gastrointestinal side effects. Limited safety data exists for adults over 75, requiring individualized risk-benefit assessment. Pediatric use of certain GLP-1 medications has been approved for ages 12 and up, but requires specialized pediatric endocrinology consultation.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Rubino D, Abramo A, Ahmann AJ, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425. PMID: 33755728
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. PMID: 33667417
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021;325(14):1403-1413. PMID: 33755729
- Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020;229:61-69. PMID: 32771410
- Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050-1061. PMID: 32441473
- Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216941
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →